Search Clinical Trials

本研究的目的是评估selinexor作为p53 wt子宫内膜癌(EC)患者维持治疗的有效性和安全性。, 谁达到了部分缓解(PR)或完全缓解(CR)(根据实体肿瘤反应评价标准第1版).1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy. 共有220名参与者将被纳入该研究，并以1:1的比例随机分配到使用selinexor或安慰剂的维持治疗.

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer

This is a Phase 1 dose-escalation study of PRT3789, a SMARCA2 degrader, 由于截断突变和/或缺失导致SMARCA4缺失的晚期或转移性实体瘤患者. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of PRT3789 monotherapy and in combination with docetaxel, describe any dose limiting toxicities (DLTs), define the dosing schedule, 并确定PRT3789后续开发中使用的最大耐受剂量(MTD)和推荐2期剂量(RP2D).

The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors.

The main questions it aims to answer are:

• 评估CPO301增加剂量的安全性和耐受性，并确定研究第二部分(A部分)的使用剂量。
• 在A部分中确定的剂量下，评估CPO301在非小细胞肺癌和其他潜在肿瘤类型患者中的安全性和耐受性(B部分)。
• To evaluate how quickly CPO301 is metabolized by the body (pharmacokinetics or PK)
• To evaluate if antibodies to the study drug develop (immunogenicity)
• To evaluate preliminary efficacy to the drug
• To correlate preliminary efficacy with mutations in a biomarker called EGFR

Participants will:

• Provide written informed consent
• Undergo screening tests to ensure they are eligible for study treatment
• 参加所有要求的研究访问，每3周静脉注射一次CPO301，直到研究医生确定应该停止研究治疗, based on how well a participant is doing on treatment
• Be followed for progression every 3 months for up to 2 years

This is a First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of HB-201 single vector therapy and HB-201 & HB-202双载体治疗HPV 16+确诊癌症患者包括两部分:I期剂量递增和II期剂量扩大.

这是一项剂量递增和剂量扩展的1/2a期试验，旨在评估DB-1305在晚期实体瘤患者中的安全性和耐受性.

This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1184 in participants with solid tumors.

参与者将患有已经扩散到全身(转移)或无法通过手术切除(不可切除)的实体瘤癌。.

The purpose of this study is to evaluate the safety, tolerability, 以及XmAb808联合派姆单抗在选定的晚期实体肿瘤患者中静脉(IV)给药的药代动力学，并确定XmAb808的最低安全和生物有效/推荐剂量(RD)和时间表.

This is a Phase 3, multicenter, open-label, nemvaleukin联合派姆单抗与方案特异性研究者选择化疗在铂耐药上皮性卵巢患者中的随机研究, fallopian tube, or primary peritoneal cancer.

IMGN853-0420 is a multicenter, open-label, 卡铂联合mirvetuximab soravtansine的2期研究，随后继续使用mirvetuximab soravtansine治疗叶酸受体α阳性, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 prior line of platinum-based chemotherapy.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. 本研究的目的是评估ABBV-400用于治疗晚期实体瘤时的不良事件和疾病活动度的变化.

ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called treatment arms. The Recommended Phase 2 dose (RP2D) will be explored. Each treatment arm receives a different dose of ABBV-400. This study will include a dose escalation phase to determine the best dose of ABBV-400, followed by a dose expansion phase to confirm the dose and combination with bevacizumab. Approximately 500 adult participants with NSCLC, 胃食管腺癌/胃食管交界腺癌(GEA)、结直肠癌(CRC)或晚期实体瘤, 将在全球范围内约7-10个剂量递增阶段的地点和85-95个剂量扩展阶段的地点纳入研究.

Dose escalation arms, participants will receive intravenous (IV) escalating doses of ABBV-400 monotherapy. Dose expansion arms, 以下晚期实体瘤适应症的参与者:egfr表达野生型非鳞状NSCLC (wtEGFR NSCLC) [Part 2i]或egfr表达突变(mutEGFR NSCLC) [Part 2ii], squamous NSCLC [Part 2iii], GEA [Part 3] will receive intravenous (IV) ABBV-400 monotherapy, participants CRC will receive IV ABBV-400 monotherapy in expansion [Part 4], participants MET amplification will receive IV ABBV-400 monotherapy in expansion [Part 5], participants MET mutation will receive IV ABBV-400 monotherapy in expansion [Part 6], CRC安全性领先的参与者将接受逐步增加剂量的IV ABBV-400联合IV贝伐单抗[Part 7a], 第7a部分确定的IV ABBV-400与IV贝伐单抗或口服trifluridine/tipiracil (TAS-102)片联合使用的低剂量或高剂量[第7b部分].

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

This is a first-in-human, phase 1a/1b, multicenter, open-label, STK-012在选定的晚期实体瘤患者中作为单药和联合派姆单抗的剂量递增研究.

IMGN151-1001 is a Phase 1, first in human, open-label dose-escalation and expansion study in adult patients with recurrent endometrial cancer, recurrent, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancers.

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson Comprehensive Cancer Center's Office of Regulatory Compliance.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.

Part 1: Dose Escalation. 本研究第1部分的主要目的是评估KB-0742在复发或难治性(R/R)实体瘤或非霍奇金淋巴瘤(NHL)患者中的安全性和耐受性。.

Part 2: Cohort Expansion. 本研究第2部分的主要目的是进一步评估KB-0742在确定的参与者队列中的安全性和耐受性.